V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320004060 | 320002490 | 1.72 | null | Palliative (P) | 2016-07-04 | 2016-08-02 | CETUXIMAB | null | N | 320016064 | CARBOPLATIN + VINCRISTINE |
| 320004061 | 320002491 | 1.64 | 54.8 | Curative (C) | 2016-07-21 | 2016-08-03 | IVADo | Y | N | 320016335 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004062 | 320005132 | 1.55 | 0 | Curative (C) | 2017-05-07 | 2017-05-25 | CARBOPLATIN + RT | N | 2 | 320016488 | IMATINIB |
| 320004063 | 320002492 | 1.78 | 64 | Palliative (P) | 2018-05-10 | 2018-05-10 | CISPLATIN + DOCETAXEL + FLUOROURACIL | N | N | 320016616 | NIVOLUMAB |
| 320004064 | 320002492 | 1.69 | 92.3 | Palliative (P) | 2017-08-09 | 2017-08-10 | ECX | 01 | N | 320016616 | CAPECITABINE |
| 320004065 | 320002492 | 1.78 | 76.2 | Neo-adjuvant (N) | 2018-03-28 | 2018-04-17 | Mitomycin Intravesical | N | N | 320016616 | CISPLATIN + GEMCITABINE |
| 320004066 | 320002493 | null | 69.7 | Adjuvant (A) | null | 2015-07-27 | Cisplatin + Docetaxel +Fluorouracil | null | null | 320016712 | IVA |
| 320004067 | 320002494 | null | 73.5 | Curative (C) | 2014-12-05 | 2014-12-07 | CHOP R - 21 days | null | null | 320016739 | CISPLATIN + ETOPOSIDE |
| 320004068 | 320005134 | null | 66.8 | Palliative (P) | 2016-04-21 | 2016-06-15 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320016753 | CAPECITABINE + CARBOPLATIN |
| 320004069 | 320002495 | null | 69.199 | Neo-adjuvant (N) | 2015-08-23 | 2015-08-24 | BEVACIZUMAB + CARBO + PACLITAXEL | 02 | N | 320016789 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 320004070 | 320002496 | 1.69 | 151 | Palliative (P) | 2016-10-18 | 2016-11-01 | Ipilimumab | N | N | 320016887 | PEMBROLIZUMAB |
| 320004071 | 320002497 | 1.5 | 88.2 | Palliative (P) | 2018-07-21 | 2018-07-29 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 320016972 | CETUXIMAB |
| 320004072 | 320002498 | 1.7 | 80 | Palliative (P) | 2013-05-12 | 2013-05-27 | EOX | N | N | 320016993 | CAPECITABINE + OXALIPLATIN |
| 320004073 | 320002499 | null | 83 | Adjuvant (A) | 2016-04-21 | 2016-04-21 | Capecitabine + Cisplatin | 2 | N | 320017019 | CAP |
| 320004074 | 320002500 | 1.8 | 98 | Curative (C) | 2014-02-26 | 2014-03-10 | CARBOPLATIN + RT | 02 | N | 320017165 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320004075 | 320002501 | 1.63 | 72 | Adjuvant (A) | 2018-02-02 | 2018-02-05 | ICON8 TRIAL | N | N | 320017210 | CETUXIMAB + RT |
| 320004076 | 320002502 | 1.77 | 80.2 | Not known (9) | null | 2013-11-25 | Cetuximab 7 day (Cycle 1) | null | null | 320017263 | CARBOPLATIN + VINORELBINE |
| 320004077 | 320002503 | null | 77.95 | null | null | 2014-05-10 | CARBOPLATIN + RT | null | null | 320017315 | NOT MATCHED |
| 320004078 | 320002504 | 1.7 | 79 | Adjuvant (A) | 2017-08-27 | 2017-08-28 | CompARE Trial | 2 | N | 320017340 | CAPECITABINE + OXALIPLATIN |
| 320004079 | 320002504 | 1.6 | 46.2 | Palliative (P) | 2017-06-04 | 2017-06-08 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 320017340 | ICON TRIAL |
| 320004080 | 320002505 | 1.66 | 80 | Palliative (P) | 2015-05-23 | 2015-06-06 | ECX | N | N | 320017509 | EOX |
| 320004081 | 320002506 | 1.66 | 53.5 | Adjuvant (A) | 2014-01-19 | 2014-01-19 | CETUXIMAB | N | N | 320017537 | CARBO + FLUOROURACIL |
| 320004082 | 320002507 | 1.79 | 85.8 | null | 2016-08-29 | 2016-09-19 | NIVOLUMAB | 02 | Y | 320017558 | CISPLATIN + GEMCITABINE |
| 320004083 | 320002507 | 1.48 | 63 | Palliative (P) | 2017-10-14 | 2017-10-14 | Capecitabine + Cisplatin | 02 | N | 320017558 | NOT MATCHED |
| 320004084 | 320002507 | 1.65 | 84.6 | Curative (C) | 2015-02-13 | 2015-02-17 | Paclitaxel (2 or 3 weekly) | 02 | N | 320017558 | BCG |
| 320004085 | 320002508 | 1.61 | 53 | Neo-adjuvant (N) | 2015-02-04 | 2015-02-12 | Cisplatin + Gemcitabine (D 1 & 8) | Y | N | 320017738 | DOXORUBICIN + IFOSFAMIDE |
| 320004086 | 320002509 | null | null | Adjuvant (A) | 2013-02-09 | 2014-10-22 | Cetuximab + Radiotherapy Load | N | N | 320017750 | PEMBROLIZUMAB |
| 320004087 | 320002510 | 1.58 | 79 | Adjuvant (A) | 2016-03-16 | 2016-03-30 | Carboplatin + Liposomal Doxorubicin | N | Y | 320017766 | CAPECITABINE |
| 320004088 | 320002511 | 1.73 | 104 | Palliative (P) | 2016-05-26 | 2016-06-11 | ECX | N | N | 320017789 | ICON TRIAL |
| 320004089 | 320002511 | 1.8 | 72 | Palliative (P) | 2014-08-29 | 2014-09-05 | Enzalutamide | N | N | 320017789 | CISPLATIN + ETOPOSIDE |
| 320004090 | 320002512 | 1.68 | 69.3 | Adjuvant (A) | 2018-05-03 | 2018-05-15 | CETUXIMAB + RT | 02 | N | 320017830 | CETUXIMAB + RT |
| 320004091 | 320002513 | 1.6 | 67.799 | Palliative (P) | 2015-10-15 | 2015-10-28 | CAPECITABINE + CARBOPLATIN + Cetuximab | Y | null | 320017929 | TRIAL |
| 320004092 | 320002514 | 1.6 | 74.2 | Neo-adjuvant (N) | 2017-06-07 | 2017-06-11 | Doxorubicin + Olaratumab | N | N | 320017934 | CETUXIMAB + RT |
| 320004093 | 320002515 | 1.56 | null | Adjuvant (A) | 2016-09-11 | 2016-09-30 | FLUOROURACIL + OXALIPLATIN | 02 | N | 320017986 | OCTREOTIDE |
| 320004094 | 320002516 | 1.79 | 57.7 | Disease modification (D) | 2017-02-19 | 2017-03-04 | Sunitinib | N | N | 320018002 | CETUXIMAB + CISPLATIN + FU |
| 320004095 | 320002516 | 1.58 | 59.2 | Disease modification (D) | 2016-05-26 | 2016-06-21 | Cisplatin + Etoposide (3 day) | 02 | null | 320018002 | ICON8B TRIAL |
| 320004096 | 320006399 | 1.57 | 93 | Palliative (P) | 2019-05-07 | 2019-06-03 | Bevacizumab + Cape + Oxali 21day | N | N | 320018067 | BEVACIZUMAB + CARBO |
| 320004097 | 320006399 | 1.87 | 75.5 | Palliative (P) | 2016-08-14 | 2016-08-15 | Cetuximab +Cisplatin + FU (Cycle 1) | N | N | 320018067 | CARBOPLATIN + VINORELBINE |
| 320004098 | 320006399 | 1.89 | 109.6 | null | 2014-12-25 | 2014-12-29 | CETUXIMAB + RT | N | N | 320018067 | CARBO + FLUOROURACIL |
| 320004099 | 320002517 | 1.78 | 66.8 | Curative (C) | 2016-12-27 | 2016-12-27 | CETUXIMAB + RT | 2 | Y | 320018267 | ENZALUTAMIDE |
| 320004100 | 320002518 | 1.52 | 52.2 | Palliative (P) | 2018-01-14 | 2018-01-14 | OCTREOTIDE | 02 | N | 320018367 | PACLITAXEL |
| 320004101 | 320002518 | 1.75 | 77 | Palliative (P) | 2017-12-21 | 2018-01-11 | CARBOPLATIN + Cetuximab + FLUOROURACIL | 02 | N | 320018367 | EOX |
| 320004102 | 320002519 | 1.7 | 64.4 | Adjuvant (A) | 2017-05-29 | 2017-06-20 | Cisplatin + Etoposide (3 day) | Y | N | 320018460 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004103 | 320002520 | 1.66 | null | Palliative (P) | 2016-12-21 | 2017-01-06 | CARBOPLATIN + RT | N | N | 320018520 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320004104 | 320002521 | 1.8 | 52.4 | Palliative (P) | 2018-02-03 | 2018-02-10 | EW EuroEwing 99 : VIDE | N | N | 320018526 | ENZALUTAMIDE |
| 320004105 | 320002521 | 1.85 | null | Neo-adjuvant (N) | 2016-09-29 | 2016-09-29 | Cisplatin + Docetaxel +Fluorouracil | null | null | 320018526 | ENZALUTAMIDE |
| 320004106 | 320002522 | 1.71 | 76 | Not known (9) | 2017-07-15 | 2017-07-31 | POUT TRIAL | N | N | 320018593 | CISPLATIN + GEMCITABINE |
| 320004107 | 320002522 | 1.58 | 65.8 | Disease modification (D) | 2018-01-23 | 2018-02-05 | Bevacizumab 7.5mg/kg | 2 | N | 320018593 | NOT MATCHED |
| 320004108 | 320002522 | 1.68 | 63.65 | Palliative (P) | 2013-10-25 | 2013-10-26 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | N | 320018593 | ICON TRIAL |
| 320004109 | 320002523 | 0 | 62.2 | Curative (C) | null | 2014-11-26 | PEMBROLIZUMAB | Y | Y | 320018739 | CISPLATIN + DOCETAXEL + FLUOROURACIL |